| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PHOENIX—A new U.S.-based pharmaceutical manufacturer, Tailstorm Health, Inc., DBA Medivant Healthcare, has announced that the company will begin to roll out sterile single dose liquid injectable medications that are on the U.S. Food and Drug Administration’s drug shortage list. Medivant’s initial products will include sterile liquid injectables that are badly needed in ICUs for patients with COVID-19.
 
Throughout the U.S., hospitals have been experiencing difficulties receiving orders for more than a dozen sedatives, anesthetics, painkillers and muscle relaxants, all of which have been in short supply. Medivant Healthcare wants to quickly fill the void and supply hospitals with safe, sterile medications.
 
“Over the long-term, Medivant seeks to be a leader in this niche area of hospital drug shortages,” said Viraj Gandhi, owner and director of Medivant Healthcare. “We are hoping to revive pharmaceutical manufacturing interest in the United States.”
 
Chandler, Arizona-based Medivant Healthcare is a boutique, cGMP (current good manufacturing practice) compliant manufacturer, which is guided by automation. Medivant’s facility is reportedly capable of producing 80,000 vials of 1-10 ML single dose liquid injectables per day, and Medivant notes that the company manufactures an average of 40,000 vials per shift, with only around 20 employees overseeing operations.
 
Medivant serves hospitals, hospital groups, surgical centers, doctors’ offices and emergency centers — a business-to-business model that provides no direct to consumer sales. The company expects rollout over the coming year to reach nearly half of the U.S., and Medivant’s current count of 16 molecules in production is expected to reach 25 or more by 2021.
 
“As a cGMP manufacturer, safety and quality are paramount and guide all decisions across the organization. Automation has led to little to no human error, and our in-house specialist QA teams work diligently to ensure compliance is met no matter how minute or seemingly insignificant the detail,” added Andrew Stasiak, director of Quality Control at Medivant Healthcare. 
 
Medivant plans to immediately begin distributing the following medications to hospitals and emergency rooms throughout the U.S.: lidocane, bupivacine, ketorolac, diltiazem, ondansetron, tramadol, calcium chloride, ketamine (based on licensing approval by the DEA), dextrose, metoprofol, ibuprofen and midazolam (also based on DEA licensing approval).

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue